3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
11
Colorectal Neoplasms
7
Gastrointestinal Neoplasms
3
Colonic Neoplasms
3
Rectal Neoplasms
2
Cholangiocarcinoma
2
Untreated Resectable Pancreatic Adenocarcinoma
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Cancer Resectable
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liver Neoplasms
1
Klatskin Tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
Gemcitabine
4
130-nm albumin-bound paclitaxel
2
sintilimab
1
nimotuzumab
1
avelumab
1
Taxes
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Hydroxychloroquine
1
Fluorouracil
1
Capecitabine
1
Antineoplastic Agents
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Cancer Resectable
×
Hydroxychloroquine
×
Gastrointestinal
×
Clear all
NCT03344172
2020-05-14
17-134
University of Pittsburgh
Phase 2
Terminated
32 enrolled
14 charts